Négociations

Le travail du Medicines Patent Pool dépend de la collaboration entre différents partenaires dans le domaine du VIH, et en particulier les partenariats avec les entreprises qui détiennent les brevets revêtent une importance capitale pour son succès.

À ce jour le Medicines Patent Pool a signé des accords de licence avec AbbVie, Bristol-Myers Squibb, Gilead Sciences, The Johns Hopkins University, MSD, Roche, Pharco Pharmaceuticals, ViiV Healthcare (partenariat entre GlaxoSmithKline, Pfizer et Shinogi) l’Université de Liverpool et le US National Institute of Health.

Le MPP a également commencé à octroyer des sous-licences aux fabricants de génériques et développeurs de produits afin que ces derniers puissent produire des médicaments à des prix abordables. En avril 2017, le MPP avait signé des accords de sous-licence avec 16 fabricants de génériques:Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab, TB Alliance and Zydus Cadila.

Le Medicines Patent Pool souhaite poursuivre le dialogue avec tous les titulaires de brevets, les fabricants de génériques et les partenariats de développement de produits jugés pertinents afin d’améliorer l’accès aux médicaments pour les personnes touchées par le VIH, l’hépatite C et la tuberculose dans les pays en développement. Le tableau ci-dessous donne un aperçu de l’avancement des négociations avec les titulaires de brevets, les fabricants de génériques et les partenariats de développement de produits.

Avancement des négociations avec les titulaires de brevets (en anglais)

Patent Holder 2017 2016 2015 2014 2013 2012 2011 2010
AbbVie Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014 In negotiations Not in negociations Not in negotiations

Reply received 26 January

Sent letter on 1 December
Boehringer-Ingelheim BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

In negotiations In negotiations In negotiations In negotiations In negotiations

Reply received 19 January

Sent letter on 1 December 
Bristol-Myers Squibb  Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013 Licence agreement for atazanavir signed in December 2013 In negotiations In negotiations

Reply received 26 January

Sent letter on 1 December
F. Hoffman-La Roche Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 In negotiations In negotiations Sent letter on 1 December
Gilead Sciences Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 Licence agreement signed in July 2011. Additional amendment made in July 2012 and November 2012 Licence agreement signed in July. Amendments made November 2011. In negotiationsReply received 14 February Sent letter on 1 December
Merck Sharp & Dohme (MSD) Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 In negotiations Not currently in negotiations Not currently in negotiations Not currently in negotiations. Reply received 28 January Sent letter on 1 December
Janssen Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Not currently in negotiations Not currently in negotiations Not currently in negotiations. J&J decision not to licence at this time Not currently in negotiations. Reply Received 31 January Sent letter on 1 December
Pharco Pharmaceuticals Licence and technology agreement for ravidasvir (RAV) in April 2017 N/A N/A N/A N/A N/A N/A N/A
University of Liverpool Collaborative Agreement to Develop HIV Nanomedicines in December 2015

 

 N/A  N/A  N/A  N/A  N/A  N/A N/A
 US National Institutes of Health Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir

In negotiations

Licence agreement signed in September 2010 for darunavir

In negotiations

 Licence agreement signed in September 2010 for darunavir
ViiV Healthcare Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in February 2013 for abacavir In negotiations In negotiations Sent letter on 1 December

 

This page is also available in: Anglais, Espagnol